Endothelial dysfunction, insulin resistance and non-insulin-dependent diabetes

Endocrinology and Metabolism, Supplement

Volumn 4, Issue 4, 1997, Pages 225-232

  Chowienczyk, Philip J ^a   Watts, Gerald F ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ALPHA TOCOPHEROL; ARGININE; ASCORBIC ACID; FIBRIC ACID DERIVATIVE; FISH OIL; FREE RADICAL; GLYCERYL TRINITRATE; GLYCOSYLATED PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; INTERMEDIATE DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METHACHOLINE; N(G) METHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; NITROPRUSSIDE SODIUM; QUINAPRIL;

ATHEROSCLEROSIS; ENDOTHELIUM INJURY; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; VASODILATATION;

EID: 0030806633     PISSN: 1074939X     EISSN: 20935978     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Stout RW. Overview of the association between insulin resistance and atherosclerosis. Metabolism 1985; 34: 7-12.
2. Steiner G. Atherosclerosis, the major complication of diabetes. London: Plenum Publishing, 1985; 277.
3. O'Brien SF, Russell JC. Insulin resistance and vascular wall function. Endocrinol. Metab. 1997; 4: 155-162.
4. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 1993; 362: 801-809.
5. Palmer RMJ, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327: 524-526.
6. Ignarro LJ, Buga GM, Wood KS, Byrns RE, Chaudhuri G. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc. Natl. Acad. Sci. USA 1987; 84: 9265-9269.
7. Bossaller C, Habib GB, Yamamoto H, Williams C, Wells S, Henry PD. Impaired muscarinic endothelium-dependent relaxation and cyclic guanosine 5′-monophosphate formation in atherosclerotic human coronary arterty and rabbit aorta. J. Clin. Invest. 1987; 79: 170-174.
8. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, Ganz P. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N. Engl. J. Med. 1986; 315: 1046-1051.
9. Zeiher AM, Drexler H, Wollschläger H, Just H. Modulation of coronary vasomotor tone in humans. Progressive endothelial dysfunction with different early stages of coronary atherosclerosis. Circulation 1991; 83: 391-401.
10. Chowienczyk PJ, Watts GF, Cockcroft JR, Ritter JM. Impaired endothelium-dependent vasodilation of forearm resistance vessels in hypercholesterolaemia. Lancet 1992; 340: 1430-1432.
11. Radomski MW, Palmer RMJ, Moncada S. Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987; ii: 1057-1058.
12. Radomski MW, Palmer RMJ, Moncada S. An L-argininenitric oxide pathway present in human platelets regulates aggregation. Proc. Natl. Acad. Sci. USA 1990; 87: 5193-5197.
13. Garg UC, Hassid A. Nitric oxide-generating vasodilators and 8-bromo-cyclic guanosine monophosphate inhibit mitogenesis and proliferation of cultured rat smooth muscle cells. J. Clin. Invest. 1989; 83: 1774-1777.
14. Kubes P, Suzuki M, Granger DN. Nitric oxide: an endogenous modulator of leukocyte adhesion. Proc. Natl. Acad. Sci. USA 1991; 88: 4651-4655.
15. Jessup W, Dean RT. Autoinhibition of murinemacrophage-mediated oxidation of low-density lipoprotein by nitric oxide synthesis. Atherosclerosis 1993; 101: 145-155.
16. 2 does not contribute to impaired endothelium-dependent relaxation. Arterioscler. Thromb. 1994; 14: 746-752.
17. Cayatte AJ, Palacino JJ, Horten K, Cohen RA. Chronic inhibition of nitric oxide production accelerates neointimal formation and impairs endothelial function in hypercholesterolemic rabbits. Arterioscler. Thromb. 1994; 14: 753-759.
18. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolaemic rabbit. J. Clin. Invest. 1992; 90: 1168-1172.
19. Laakso M, Edelman SV, Brechtel G, Baron AD. Decreased effects of insulin to stimulate skeletal muscle blood flow in obese man: a novel mechanism for insulin resistance. J. Clin. Invest. 1990; 85: 1844-1853.
20. Laakso M, Edelman SV, Olefsky JM, Brechtel G, Wallace P, Baron AD. Kinetics of in vivo muscle insulin mediated glucose uptake in human obesity. Diabetes 1990; 39: 965-974.
21. Laakso M, Edelman SV, Brechtel G, Baron AD. Impaired insulin-mediated skeletal blood flow in patients with NIDDM. Diabetes 1192; 41: 1076-1083.
22. Anderson EA, Mark AL. The vasodilator action of insulin. Implications for the insulin hypothesis of hypertension. Circulation 1993; 21: 136-141.
23. Scherrer U, Randin D, Vollenweider P, Vollenweider L, Nicod P. Nitric oxide release accounts for insulin's vascular effects in humans. J. Clin. Invest. 1994; 94: 2511-2515.
24. Paternostro G, Camici PG, Lammerstma AA, Marinho N, Baliga RR, Kooner JS, Radda GK, Ferrannini E. Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. J. Clin. Invest. 1996; 98: 2094-2099.
25. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
26. Zeiher AM, Drexler H, Wollschläger H, Just H. Endothelial dysfunction of the coronary microvasculature is associated with impaired coronary blood flow regulation in patients with early atherosclerosis. Circulation 1991; 84: 1984-1992.
27. Whitney RJ. The measurement of volume changes in human limbs. J. Physiol. (Lond). 1953; 121: 1-27.
28. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb DJ. Measuring forearm blood flow and interpreting the response to drugs and mediators. Hypertension 1995; 25: 918-923.
29. Ciccone M, DiNoia D, DiMichele L, Corriero F, DiBiase M, Biasco MG, Novo S, Strano A, Rizzon P. The incidence of asymptomatic extracoronary atherosclerosis in patients with coronary atherosclerosis. Int. Angiol. 1993; 12: 25-28.
30. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd FK, Deanfield JE. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992; 340: 1111-1115.
31. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, Lüscher TF. Nitric oxide is responsible for flow-dependent dilation of human peripheral conduit arteries in vivo. Circulation 1995; 88: 2511-2516.
32. Celermajer DS, Adams MR, Clarkson P, Robinson J, McCredie R, Donald A, Deanfield JE. Passive smoking and impaired endothelium-dependent arterial dilation in healthy young adults. N. Engl. J. Med. 1996; 334: 150-154.
33. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE. Cigarette smoking is associated with dose-related and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation 1993; 88: 2149-2155.
34. Sorensen KE, Celermajer DS, Georgakopoulos D, Hatcher G, Beteridge DJ, Deanfield JE. Impairement of endothelium-dependent dilation is an early event in children with familial hypercholesterolaemia and is related to the lipoprotein (a) level. J. Clin. Invest. 1994; 93: 50-55.
35. Jaap AJ, Hammersly MS, Shore AC, Tooke JE. Reduced microvascular hyperaemia in subjects at risk of developing tye 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1994; 37: 214-216.
36. Morris SJ, Shore AC, Tooke JE. Responses of the skin microcirculation to acetylcholine and sodium nitroprusside in patients with NIDDM. Diabetologia 1995; 38: 1337-1344.
37. Petrie JR, Ueda S, Webb DJ, Elliot HL, Connell JMC. Endothelial nitric oxide production and insulin sensitivity: a physiological link with implications for pathogenesis of cardiovascular disease. Circulation 1996; 93: 1331-1333.
38. Steinberg HO, Chaker H, Learning R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J. Clin. Invest. 1996; 97: 2601-2610.
39. G-monomethyl-L-arginine of vasodilator effects of acetylcholine and methacholine in human forearm vasculature. Br. J. Pharmacol. 1993; 110: 736-738.
40. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR. Impaired endothelium-dependent and independent vasodilation in patients with Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1992; 35: 771-776.
41. Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Am. Coll. Cardiol. 1996; 27: 567-574.
42. Watts GF, O'Brien SF, Silvester W, Millar JA. Impaired endothelium-dependent and independent dilation of forearm resistance arteries in men with diet treated non-insulin dependent diabetes; role of dyslipidaemia. Clin. Sci. 1996; 91: 567-573.
43. Goodfellow J, Ramsey MW, Luddington LA, Jones CJH, Coates PA, Dunstan F, Lewis MJ, Owens DR, Henderson AH. Endothelium and inelastic arteries: an early marker of vascular dysfunction in non-insulin-dependent diabetes. BMJ 1996; 312: 744-745.
44. Chowienczyk PJ, Barnes DJ, Brett SE, Cockcroft JR, Viberti GC, Ritter JM. Correction of impaired NO mediated vasodilation by L-arginine in non-insulin-dependent diabetics. Endothelium 1995; 3: s95. (Abstract)
45. Ting HH, Timimi FK, Boles KS, Creager SJ, Ganz P, Creager MA. Vitamin C improves endothelium-dependent vasodilation in patients with non-insulin-dependent diabetes mellitus. J. Clin. Invest. 1996; 97: 22-28.
46. Tribe RM, Poston L. Oxidative stress and lipids in diabetes: a role in endothelium vasodilator dysfunction ? Vase. Med. 1996; 1: 195-206.
47. Drexler H, Zeiher AM. Endothelial function in human coronary arteries in vivo. Focus on hypercholesterolaemia. Hypertension 1991; 18[II]: II-90-II-99.
48. Ting HH, Timimi FK, Haley EA, Roddy M-A, Ganz P, Creager MA. Vitamin C restores endothelium-dependent vasodilation in patients with hypercholesterolaemia. Circulation 1996; 94: 1402.
49. Drexler H, Zeiher AM, Meinzer K, Just H. Correction of endothelial dysfunction in the coronary microcirculation of hypercholesterolaemic patients by L-arginine. Lancet 1991; 338: 1546-1550.
50. Panza JA, Casino PR, Badar DN, Quyyumi AA. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential hypertension. Circulation 1993; 87: 1475-1481.
51. Clarkson P, Celermajer DS, Donald AE, Sampson M, Sorensen KE, Adams M, Betteridge DJ, Deanfield JE. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J. Am. Coll. Cardiol. 1996; 28: 573-579.
52. Laakso M, Voutilainen E, Sarlund H, Aro A, Pyorala K, Penttila I. Serum lipids and lipoproteins in middle-aged non-insulin-dependent diabetics. Atherosclerosis 1985; 56: 271-289.
53. Chowienczyk PJ, Watts GF, Wierzbicki AS, Cockcroft JR, Brett SE, Ritter JM. Preserved endothelial function in patients with severe hypertriglyceridaemia and low functional lipoprotein lipase activity. J. Am. Coll. Cardiol. 1997; 29: 964-968.
54. Zilversmit DB. Atherogenesis: a postprandial phenomenon. Circulation 1979; 60: 473-485.
55. Zeiher AM, Schächinger V, Hohnloser SH, Saurbier B, Just H. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Circulation 1994; 89: 2525-2532.
56. Austin MA, Edwards KL. Small, dense low density lipoproteins, the insulin resistance syndrome and non-insulin-dependent diabetes. Curr. Opin. Lipidol. 1996; 7: 167-171.
57. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willet WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988; 260: 1917-1921.
58. Tribble DL, Holl LG, Wood PD, Krauss RM. Variations in oxidative susceptibility among six low density lipoprotein subfractions of differing density and particle size. Atherosclerosis 1992; 93: 189-199.
59. Sundaram RK, Bhaskar A, Vijayalingam S, Viswanathan M, Mohan R, Shanmugasundaram KR. Antioxidant status and lipid peroxidation in type II diabetes mellitus with and without complications. Clin. Sci. 1996; 90: 255-260.
60. 2α levels are elevated in individuals with non-insulin-dependent diabetes mellitus. FEBS Lett. 1995; 368: 225-229.
61. Jacobs M, Plane F, Bruckdorfer KR. Native and oxidized low-density lipoproteins have different inhibitory effects on endothelium-derived relaxing factor in rabbit aorta. Br. J. Pharmacol. 1990; 100: 21-26.
62. Liao JK. Inhibition of Gi proteins by low density lipoproteins attenuates bradykinin stimulated release of endothelial derived nitric oxide. J. Biol. Chem. 1994; 269: 12987-12992.
63. i2 subunit expression by oxidised low-density lipoprotein. J. Clin. Invest. 1995; 95: 1457-1463.
64. Liao JK, Shin WS, Lee WY, Clark SL. Oxidised low density lipoprotein decreases the expression of endothelial nitric oxide synthase. J. Biol. Chem. 1995; 270: 319-324.
65. Hirata K, Miki N, Kuroda Y, Sakoda T, Kawashima S, Yokoyama M. Low concentrations of oxidized low-density lipoprotein and lysophosphatidylcholine upregulate constitutive nitric oxide mRNA expression in bovine aortic endothelial cells. Circ. Res. 1995; 76: 958-962.
66. Pritchard KA, Groszek L, Smalley DM, Sessa WC, Wu M, Villalon P, Wolin MS, Stemerman MB. Native low-density lipoprotein increases endothelial cell nitric oxide synthase generation of superoxide anion. Circ. Res. 1995; 77: 510-518.
67. Griffith OW, Stuehr DJ. Nitric oxide synthases:properties and catalytic mechanism. Annu. Rev. Physiol. 1995; 57: 707-736.
68. Rubanyi GM, Vanhoutte PM. Superoxide anions and hypoxia inactivate endothelium-derived relaxing factor. Am. J. Physiol. 1986; 250: H822-H827.
69. Hawthorne GC, Bartlett K, Hetherington CS, Alberti KGMN. The effect of high glucose on polyol pathway activity and myo-inositol metabolism in cultured human endothelial cells. Diabetologia 1989; 32: 163-166.
70. Wolff SP. Diabetes mellitus and free radicals. Free radicals, transition metals and oxidative stress in the aetiology of diabetes mellitus and complications. Br Med Bull 1993; 49: 642-652.
71. Poston L, Taylor PD. Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. Clin. Sci. 1995; 88: 245-255.
72. Morrow JD, Roberts LJ. The isoprostanes. Current knowledge and directions for future research. Biochem. Pharmacol. 1996; 51: 1-9.
73. Makita Z, Radoff S, Rayfield EJ, Yang Z, Skolnik E, Delaney V, Friedman EA, Cerami A, Vlassara H. Advanced glycosylation end products in patients with diabetic nephropathy. N. Engl. J. Med. 1991; 325: 836-842.
74. Wautier JL, Wautier MP, Schmidt AM, Anderson GM, Hori O, Zoukourian C, Capron L, Chappey O, Yan SD, Brett J. Advanced glycation end products (AGEs) on the surface of diabetic erythrocytes bind to the vessel wall via a specific receptor inducing oxidant stress in the vasculature: a link between surface-associated AGEs and diabetic complications. Proc. Natl. Acad. Sci. USA 1994; 91: 7742-7746.
75. Bucala R, Makita Z, Koshinsky T, Cerami A, Vlassara H. Lipid advanced glycosylation: pathway for lipid oxidation in vivo. Proc. Natl. Acad. Sci. USA 1993; 90: 6434-6438.
76. Bucala R, Tracey KJ, Cerami A. Advanced glycosylation end products quench nitric oxide and mediate defective endothelium-dependent vasodilation in experimental diabetes. J. Clin. Invest. 1991; 87: 432-438.
77. McVeigh GE, Brennan GM, Johnston GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR. Dietary fish oil augments nitric oxide production or release in patients with Ty pe 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 33-38.
78. Mancini GB, Henry GC, Macaya C, O'Neill BJ, Pucillo AL, Carere RG, Wargovich TJ, Mudra H, Lüscher TF, Kubaner MI, Haber HE, Uprichard AC, Pepine CJ, Pitt B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation 1996; 94: 240-243.
79. Stroes ESG, Koomans HA, de Bruin TWA, Rabelink TJ. Vascular function in the forearm of hypercholesterolaemic patients off and on lipid-lowering medication. Lancet 1995; 346: 467-471.
80. O'Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95: 1126-1131.
81. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N. Engl. J. Med. 1995; 332: 481-487.
82. Nolan JJ, Ludvick B, Beerdsen P, Joyce M, Olefsky J. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N. Engl. J. Med. 1994; 331: 1188-1193.
83. Noguchi N, Sakai H, Kato Y, Tsuchiya J, Yamamoto Y, Niki E. Inhibition of oxidation of low density lipoprotein by troglitazone. Atherosclerosis 1996; 123: 227-234.
84. Paolisso G, Balbi V, Volpe C, Varricchio G, Gambardella A, Saccomanno F, Ammendola S, Varricchio M, D'Onofrio F. Metabolic benefits deriving from chronic vitamin C supplementation in aged non-insulin dependendent diabetics. J. Am. Coll. Nutr. 1995; 14: 387-392.